Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels

Various protein kinases are implicated in the pathogenesis of human cervical cancer and many kinase inhibitors have been used to regulate the activity of protein kinases involved in the disease signaling networks. In the present study, a systematic kinase-inhibitor interactome is created for various small-molecule inhibitors across diverse cervical cancer-related kinases by using ontology enrichment, molecular docking, dynamics simulation and energetics analysis. The interactome profile is examined in detail with heatmap analysis and heuristic clustering to derive promising inhibitors that are highly potential to target the kinome of human cervical cancer in a multi-target manner. A number of hit and unhit inhibitors are selected and their cell-suppressing effects are tested against human cervical carcinoma HeLa, from which several inhibitor compounds with high cytotoxicity are successfully identified. A further kinase assay confirms that these inhibitors can generally target their noncognate kinases HER3 and BRaf in cervical cancer with a high or moderate activity; the activity profile are comparable with or even better than that of cognate kinases inhibitors, with IC50 values ranging between 4.8 and 340.6 nM for HER3 and between 37.2 and 638.2 nM for BRaf. This work would help to identify those unexpected kinase-inhibitor interactions in human cervical cancer and to develop new and efficient therapeutic strategy combating the disease.

[1]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[2]  B. Gabrielli,et al.  Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors , 2017, Molecular Cancer Therapeutics.

[3]  María Martín,et al.  UniProt: A hub for protein information , 2015 .

[4]  Li Meng,et al.  In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway , 2018, Comput. Biol. Chem..

[5]  J. LaBaer,et al.  Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Peng Zhou,et al.  Indirect Readout in Protein-Peptide Recognition: A Different Story from Classical Biomolecular Recognition , 2014, J. Chem. Inf. Model..

[7]  Jian Huang,et al.  Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis , 2016, Journal of biomolecular structure & dynamics.

[8]  Jun Yao,et al.  Chemotherapy Drug Response to the L858R‐induced Conformational Change of EGFR Activation Loop in Lung Cancer , 2016, Molecular informatics.

[9]  N. Nour Cervical cancer: a preventable death. , 2009, Reviews in obstetrics & gynecology.

[10]  Paul D. Smith,et al.  AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer , 2010, Clinical Cancer Research.

[11]  Yuan Wang,et al.  Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel , 2018, Cell cycle.

[12]  D. Grueneberg,et al.  Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines , 2008, Proceedings of the National Academy of Sciences.

[13]  P. Zhou,et al.  Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands , 2018, Artificial cells, nanomedicine, and biotechnology.

[14]  C. Pérez-Plasencia,et al.  Targeted treatments for cervical cancer: a review , 2012, OncoTargets and therapy.

[15]  Xi-wei Ding,et al.  Molecular design of Stat3‐derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer , 2018, Journal of molecular recognition : JMR.

[16]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[17]  H. Matter,et al.  Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes. , 2002, Journal of medicinal chemistry.

[18]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[19]  T. Jenssen,et al.  A literature network of human genes for high-throughput analysis of gene expression , 2001 .

[20]  Anthony Nicholls,et al.  Confidence limits, error bars and method comparison in molecular modeling. Part 1: The calculation of confidence intervals , 2014, Journal of Computer-Aided Molecular Design.

[21]  Kurre Purna Nagasree,et al.  AUDocker LE: A GUI for virtual screening with AUTODOCK Vina , 2011, BMC Research Notes.

[22]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[23]  Stephen D. Pickett,et al.  Classification of Kinase Inhibitors Using BCUT Descriptors , 2000, J. Chem. Inf. Comput. Sci..

[24]  H. Rupasinghe,et al.  Kinase-targeted cancer therapies: progress, challenges and future directions , 2018, Molecular Cancer.

[25]  P. Kollman,et al.  A well-behaved electrostatic potential-based method using charge restraints for deriving atomic char , 1993 .

[26]  Chao Yang,et al.  What are the ideal properties for functional food peptides with antihypertensive effect? A computational peptidology approach. , 2013, Food chemistry.

[27]  Rosalin Mishra,et al.  HER3 signaling and targeted therapy in cancer , 2018, Oncology reviews.

[28]  Henry C Kitchener,et al.  Human papillomavirus and cervical cancer , 2013, The Lancet.

[29]  L. Pinna,et al.  Casein kinases as potential therapeutic targets , 2016, Expert opinion on therapeutic targets.

[30]  A. Longatto-Filho,et al.  HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors , 2017, Theranostics.

[31]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[32]  Jian Huang,et al.  Structural and energetic insights into the intermolecular interaction among human leukocyte antigens, clinical hypersensitive drugs and antigenic peptides , 2015 .

[33]  Chao Yang,et al.  Self-Binding Peptides: Folding or Binding? , 2015, J. Chem. Inf. Model..

[34]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[35]  J. Fonseca-Moutinho Smoking and Cervical Cancer , 2011, ISRN obstetrics and gynecology.

[36]  Lenwood S. Heath,et al.  H++: a server for estimating pKas and adding missing hydrogens to macromolecules , 2005, Nucleic Acids Res..

[37]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[38]  Jian Huang,et al.  A two-step binding mechanism for the self-binding peptide recognition of target domains. , 2016, Molecular bioSystems.

[39]  A. Dueñas-González,et al.  HER2 expression in cervical cancer as a potential therapeutic target , 2004, BMC Cancer.

[40]  Jacob K. Asiedu,et al.  The Drug Repurposing Hub: a next-generation drug library and information resource , 2017, Nature Medicine.

[41]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[42]  Huanxiang Liu,et al.  Understanding the molecular basis of MK2-p38α signaling complex assembly: insights into protein-protein interaction by molecular dynamics and free energy studies. , 2012, Molecular bioSystems.

[43]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[44]  Jae-Hoon Jeong,et al.  Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer. , 2018, International journal of oncology.

[45]  Peng Zhou,et al.  Targeting Self-Binding Peptides as a Novel Strategy To Regulate Protein Activity and Function: A Case Study on the Proto-oncogene Tyrosine Protein Kinase c-Src , 2017, J. Chem. Inf. Model..

[46]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[47]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[48]  Peng Xie,et al.  Identification of a novel family of BRAF(V600E) inhibitors. , 2012, Journal of medicinal chemistry.

[49]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[50]  Hong-Fang Chen,et al.  Protein-drug interactome analysis of SSRI-mediated neurorecovery following stroke , 2014, Biosyst..

[51]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  G. Keserű,et al.  Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery. , 2017, Current topics in medicinal chemistry.

[53]  Yoshikazu Ohta,et al.  Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein , 2011, The Journal of Biological Chemistry.

[54]  Lei Yuan,et al.  Systematic analysis and identification of unexpected interactions from the neuroprotein drug interactome in hydrocephalus pharmacological intervention , 2019, J. Bioinform. Comput. Biol..

[55]  Chao Yang,et al.  Biomacromolecular quantitative structure–activity relationship (BioQSAR): a proof-of-concept study on the modeling, prediction and interpretation of protein–protein binding affinity , 2013, Journal of Computer-Aided Molecular Design.

[56]  Xiaobing Chen,et al.  Statistical analysis and heuristic identification of unexpected interactions from the neurokinase‐inhibitor interactome in trigeminal neuralgia pharmacological intervention , 2019, Journal of Chemometrics.

[57]  Ranran Zhang,et al.  Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast? , 2011, Leukemia & lymphoma.

[58]  Leming Shi,et al.  Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. , 2015, Combinatorial chemistry & high throughput screening.

[59]  H. Gohlke,et al.  Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method , 2012, Molecular informatics.

[60]  Y. Dobashi,et al.  Molecularly Targeted Therapy: Past, Present and Future , 2012 .

[61]  Hongyan Zhu,et al.  Integrative identification of unexpected kinase-inhibitor interactions in the MAPK-mediated proliferation and differentiation of Mc3T3-E1 osteoblasts. , 2019, General physiology and biophysics.

[62]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[63]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[64]  Shamala Devi Sekaran,et al.  Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae , 2015, PloS one.

[65]  G. Kroemer,et al.  Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. , 2017, Gastroenterology.